- Mardan blast toll rises to 34, as four more die overnight
- Electricity shortfall reduced to 3950 MW
- Budget brings the poor on brink of death: Sheikh Rasheed
- Pakistan to respect gas pipeline project
- Balochistan cabinet administered oath
- Govt, opposition should jointly frame policy on drone strikes: Imran
- APC to be convened on drone attacks, terrorism: Ch Nisar
- Long awaited: Imran finally takes oath as MNA
- PM directs officials to speed up Neelum-Jhelum Hydro Power Project
- Power tariff goes up by Rs 1.12 per unit
Health
Dated: 2012-07-06
In a bid to link pioglitazone and bladder cancer, researchers conducted a systematic review and analysis of clinical trials and observational studies involving over 2.6 million patients.
"We observed an increased risk of bladder cancer associated with the use of thiazolidinediones," writes Jeffrey Johnson from the School of Public Health, University of Alberta and study co-author, the Canadian Medical Association Journal reports.
Thiazolidinediones, including Pioglitazone, introduced in the late 1990s, are also known as glitazones, a class of drugs used in the treatment of type 2 diabetes, according to an Alberta statement. "In particular, use of pioglitazone was associated with an increased risk of bladder cancer based on a pooled estimate from three cohort studies involving more than 1.7 million individuals," adds Johnson.
The researchers also looked at a possible association with rosiglitazone, another type of thiazolidinedione, but did not see an effect.
<<Go back
